WALTHAM, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) announced today that Elhan Webb has joined the Company as Head of Investor Relations and External Communications.
“We are very fortunate to have someone of Elhan’s caliber to drive our Investor Relations strategy during a pivotal time in the evolution of Radius,” said Jesper Høiland, President and Chief Executive Officer of Radius Health. “Elhan’s considerable global experience in working with both sell-side and buy-side analysts as well as her experience as an investment portfolio manager uniquely position her to head Radius’ Investor Relations program.”
Ms. Webb is a CFA® charterholder and joins Radius from Genfit Corporation where she was Vice President and Head of Investor Relations. During her diverse international career, she established a reputation as a forward-thinking investor relations strategist, business development leader, and investment portfolio manager at global companies. She spent more than a decade in Europe managing and leading investments in the healthcare sector at financial institutions such as BB Biotech-Bellevue Asset Management, UBS and Lombard Odier. At Roche Group, she led investor relations activities for Roche Diagnostics, the world's largest in-vitro diagnostics player. She also held business development roles at Roche Molecular Diagnostics, U.S. and Morphochem.
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. For more information, visit www.radiuspharm.com, and follow us on Twitter and LinkedIn.
Investor & Media Relations Contact:
Source:Radius Health Inc.